DALLAS, Oct. 27, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Elan Corp. Plc. (NYSE:ELN). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Elan Corp. Plc. (NYSE:ELN) should be of particular interest to other biotechnology and drug companies: Gilead Sciences Inc. (Nasdaq:GILD), Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://www.investorsoup.com/lp/ELN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Elan Corporation plc (ELN) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. ELN's operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain.
Message Board Search for ELN: http://www.boardcentral.com/boards/ELN
In the report, the analyst notes:
"A European panel has started a review of controversial Multiple Sclerosis drug Tysabri, sold by Biogen Idec Inc. and ELN, citing a much higher number of rare brain infections than previously disclosed. The European Medicines Agency's Committee for Medicinal Products for Human Use, commonly called CHMP, reported that there are 23 cases of progressive multifocal leukoencephalopathy, or PML, since the drug's launch. Previously, there had only been 13 confirmed cases of the infection since the drug re-entered the market in 2006, following an 18-month removal that was prompted by a link to three previous cases of PML. The drug is key to the growth of both companies, and this recent news had Biogen shares recently trading down 5.8% to $44.49, while ELN's American depository receipts fell 20% to $5.17.
"For the second quarter of 2009, Tysabri in-market net sales increased by 27% to $253.8 million, up from $200.0 million for the same period of 2008. The increase reflects strong patient demand across global markets."
To read the entire report visit: http://www.investorsoup.com/lp/ELN
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.